Eight Chinese Biopharma Companies, Including Shenzhou Bio and Xuanjing Bio, Secure Over RMB 100 Million Each in Funding This Week

　　【Pharmaceutical Network Industry DynamicsAccording to incomplete industry statistics, this week (October 19th-25th), a total of 9 companies in China's pharmaceuticals and health sector received financing. Among them, 8 biopharmaceutical companies raised over 100 million yuan each, including XsellSmart, Rigerna, and others.
 

Specifically, BIOYOND Robotics announced on October 25 the successful completion of its Series A3 round of financing worth several hundred million yuan. This round of financing was led by Puhua Capital, with continued investment from Qiming Venture Partners and Boyuan Capital. BIOYOND Robotics integrates cutting-edge...RobotTechnology, high-precision visual recognition, and cutting-edge artificial intelligence techniques have been leveraged to create a series of groundbreaking, easy-to-use, and unmanned intelligent automation products and solutions tailored for various laboratories in scientific research, clinical diagnostics, and physicochemical applications, redefining industry application standards.
 

RAYSHAPE announced on October 24 the completion of an over RMB100 million Series A round of financing. This round was led by Unity Ventures, with several senior entrepreneurs from the dental industry participating as follow-up investors. Index Capital served as the exclusive financial advisor. The funds will mainly be used for capacity expansion and overseas market development.
 

MacroLux Medical Technology Co., Ltd. announced on October 23 that the company had completed a Series B financing round of over RMB 100 million. This round of financing will help MacroLux further expand production capacity, accelerate new product development, and expedite global market expansion, driving its rapid growth in the disposable endoscope field. On the same day, Zedman Pharmaceuticals also announced the completion of a nearly RMB 100 million Series A+ financing round, led by Qingdao Guoxin, with additional investments from shareholders Bennu Capital, Hanking Capital, and Beta Fund. The funds will mainly be used to accelerate the research and development, clinical studies, and commercial promotion of multiple therapeutic drugs targeting the aryl hydrocarbon receptor (AhR) for autoimmune inflammatory diseases.
 

Union Strong Announces Good News on October 21: The Company Secures D+ Round Financing of RMB 100 Million, Led by Beijing Medical and Health Industry Investment Fund, with Beijing Economic and Technological Development Zone Industrial Upgrade Equity Investment Fund Following Suit. After this round of financing, the company plans to further integrate its core product — the intelligent solution for intracranial aneurysm surgery — into the intelligent manufacturing system, achieving automation in the production process by introducing flexible production lines.
 

XsellSmart Announces Over 100 Million Yuan in B1 Round Market-Oriented Financing on October 21
 

On the same day, BioPioneer Tech announced the completion of a nearly RMB 100 million Pre-A round of financing. This round of investment was led by SDIC Venture Capital, with participation from Rugao Innovation Investment, and XiQiao Capital serving as the exclusive financial advisor. The funds raised will be used to further enhance the mass production and commercial promotion of biomanufacturing products.
 

Rigerna announced on October 21 the completion of an angel+ round of financing exceeding RMB 100 million. This round was co-led by Shanghai Science Investment and Qihang Investment, with participation from Xincheng Fund, JSG United Runpu, Yuanxi Haihe, and others. The proceeds will primarily be used for the clinical research of the company’s leading siRNA drug RG002C0106, the advancement of multiple preclinical pipelines, and the rapid development of non-liver tissue in vivo delivery technology and corresponding pipelines.
 

Overall, companies that received financing of more than 100 million yuan this week mainly cover fields such as dentistry and neurology. These areas often have significant market development potential, and with increased capital investment, it will help promote the R&D and commercialization process of corporate products.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.